logo

For the Inventor, By the Inventor

Potomac, MD, United States of America

Zhi-yong Yang

This inventor holds 26 USPTO granted patents and 7 published patent applications and 7 EPO patents, primarily in HIV Vaccine Development. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Michigan, University of Washington. Active years: 1997-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhi-yong Yang. Retrieved from https://idiyas.com/inventor/zhi-yong-yang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 73.1

 

Average Co-Inventor Count = 5.1

ph-index = 9

Forward Citations = 228(Granted Patents)


Location History:

  • Ann Arbor, MI (US) (1997 - 2006)
  • Potomac, MD (US) (2006 - 2020)

Company Filing History:

goldMedal19 out of 3,696 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
silverMedal6 out of 3,536 
 
University of Michigan
 patents
bronzeMedal4 out of 2,172 
 
University of Washington
 patents
4. 2 out of 71 
 
International Aids Vaccine Initiative
 patents
5. 2 out of 1,208 
 
Scripps Research Institute
 patents
6. 1 out of 88 
 
Genvec, Inc.
 patents
7. 1 out of 1 
 
Genvex, Inc.
 patent
where one patent can have more than one assignee

Years Active: 1997-2020

Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Antibodies
Broadly Neutralizing
Vaccine Development
Multiclade Immune Response
Filovirus Infection
Recombinant Expression
Gene Therapy
Nucleic Acids
Adenoviral Vectors
Cancers Treatment
Restenosis Therapy
Immunization Methods
26 patents (USPTO):Explore Patents
1. 10815295 - Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein (2020-10-27),
2. 10035845 - Neutralizing antibodies to HIV-1 and their use (2018-07-31),
3. 10035844 - Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein (2018-07-31),
4. 9796774 - HIV-1 broadly neutralizing antibodies (2017-10-24),
5. 9738703 - Neutralizing antibodies to HIV-1 and their use (2017-08-22),
6. 9695230 - Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein (2017-07-04),
7. 9382311 - HIV-1 broadly neutralizing antibodies (2016-07-05),
8. 9175070 - Neutralizing antibodies to HIV-1 and their use (2015-11-03),
9. 9012618 - Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures (2015-04-21),
10. 8637036 - Neutralizing antibodies to HIV-1 and their use (2014-01-28),
11. 8454972 - Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen (2013-06-04),
12. 8323961 - HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV (2012-12-04),
13. 8124592 - Development of a preventive vaccine for filovirus infection in primates (2012-02-28),
14. 8106027 - Development of a preventive vaccine for filovirus infection in primates (2012-01-31),
15. 8106026 - Development of a preventive vaccine for filovirus infection in primates (2012-01-31),

Title: Zhi-yong Yang: A Pioneer in HIV Research and Antibody Development

Introduction

Zhi-yong Yang, based in Potomac, MD, is an influential figure in the field of biomedical research, particularly known for his significant contributions to the development of broadly neutralizing antibodies against HIV-1. With a remarkable record of 26 patents, Yang's innovations are paving the way for advancements in HIV detection and treatment.

Latest Patents

Among Yang's latest patents are groundbreaking inventions focused on broadly neutralizing HIV-1 antibodies that target the CD4-binding site of the envelope protein. One such patent outlines monoclonal neutralizing antibodies that specifically interact with HIV-1 gp120, along with antigen-binding fragments. These patents also encompass nucleic acids encoding the antibodies, associated vectors, and host cells. Methods for detecting HIV utilizing these antibodies have been developed, providing novel approaches to prevent and treat HIV infections. Another associated patent further details VRC07 antibodies that bind to the same critical site on the envelope protein, expanding the arsenal against HIV.

Career Highlights

Yang's career is distinguished by his tenure at prominent institutions, including the United States of America, as represented by the Secretary, Department of Health and Human Services, and the University of Michigan. His work at these organizations has significantly influenced the field of infectious diseases, particularly through the development of therapies aimed at combating HIV.

Collaborations

Throughout his career, Zhi-yong Yang has collaborated with several renowned researchers, notably Gary J. Nabel and John R. Mascola. Together, they have pooled their knowledge and expertise to drive forward innovative research aimed at addressing the challenges presented by HIV.

Conclusion

Zhi-yong Yang's contributions to HIV research through his innovative patents have the potential to change the landscape of treatment and prevention strategies. His persistent efforts to develop effective therapeutic options continue to inspire and impact the scientific community, marking him as a leading innovator in the ongoing fight against HIV.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…